Singapore's Covid-19 wave eases as weekly cases and hospitalisation numbers dip
The latest data shows the number of hospitalisations has decreased to about 118 cases daily. -- PHOTO: ST FILE
SINGAPORE (The Straits Times/ANN): Singapore's recent Covid-19 wave is easing, with the number of cases dipping to about 15,300 weekly, said Minister of Health Ong Ye Kung.
The latest data, which Mr Ong called 'encouraging', also shows the number of hospitalisation cases has decreased to about 118 daily.
In his Facebook post on June 14, he added that when the wave first picked up in late April, the Republic saw the estimated weekly infections spike to about 26,400 cases.
Healthcare institutions in Singapore also faced increased patient load, with daily Covid-19 hospitalisation cases reaching around 174.
'The good news is that ICU (intensive care unit) cases remained consistently low throughout this wave, staying at just about two to three cases daily,' Ong said.
'This shows how our healthcare system has built up stronger resilience in managing Covid-19.'
Amid signs that the wave is slowing down, he said that wastewater surveillance readings have also declined, referring to the quick and accurate barometer to detect diseases.
In his post, Ong reminded the public that similar to seasonal influenza, such Covid-19 waves can still put pressure on Singapore's healthcare system.
He added that Singaporeans must continue to prepare for new pandemics or future waves.
'We will keep monitoring the situation closely, particularly the emergence of new variants, and update the public accordingly,' he said. - The Straits Times/ANN
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
16 hours ago
- New Straits Times
No Zika cases in Johor, but state on high alert after Singapore infections
JOHOR BARU: There are no Zika cases reported in Johor, despite two confirmed infections in Singapore. Following the recent cases reported across the Causeway, health authorities are on high alert and have heightened mosquito control and health surveillance. State Health and Environment Committee chairman Ling Tian Soon said entry protocols remain unchanged at all land, sea and air checkpoints to Johor. "Singaporeans and other foreigners can continue to make their way into Johor. "Screening protocol will continue at all entry checkpoints…anyone showing symptoms will be immediately referred for further testing at designated medical facilities," he told the New Straits Times today. "There are no reported Zika cases in Johor as of now, and the Health Ministry has not issued any new directives. However, we remain vigilant," Ling added. There are two confirmed Zika cases in Singapore's housing estate in Woodlands, some 5km away from the Johor's border land entry point via the Customs, Immigration and Quarantine (CIQ) complex at the Bangunan Sultan Ismail, here. While Malaysia has not seen a Zika outbreak since 2016, Ling stressed the need for continuous preventive efforts, especially in Johor given its high volume of cross-border traffic. Malaysia's last significant Zika concern occurred in 2016, when the first local transmission was confirmed in Sabah, shortly after Singapore reported a major outbreak in the Aljunied area. Since then, Malaysia has reported sporadic cases, primarily imported or isolated incidents, but no major outbreak or cluster has been officially recorded. As of June 2025, there has been no confirmed Zika outbreak in Malaysia resembling the 2016 episode in terms of scale or transmission pattern. Meanwhile, Singapore National Environment Agency (NEA) in a statement issued on June 19 (Thursday) said NEA and the Communicable Diseases Agency (CDA) confirmed two locally transmitted Zika cases at Woodlands Street 11 and Street 32. The viral traces were found in both mosquito and wastewater samples in the area which signalled a likely transmission. Singapore, has deployed over 70,000 mosquito traps across the island, has recorded seven confirmed Zika cases this year. The virus is spread mainly by Aedes mosquitoes, which is the same vector responsible for dengue. It can cause serious complications in pregnant women, including birth defects. Zika symptoms include fever, rash, red eyes, and joint pain, although many infected individuals remain asymptomatic. There is currently no vaccine or specific treatment. Ling urged Johoreans to stay alert and practise anti-mosquito measures such as removing stagnant water and using repellents. He also advised pregnant women and those planning to travel to affected areas to consult medical professionals if they develop symptoms. The public can follow updates through official channels and are advised to seek immediate medical attention if unwell.
New Straits Times
17 hours ago
- New Straits Times
No Zika cases in Johor, but state on high alert
JOHOR BARU: There are no Zika cases reported in Johor, despite two confirmed infections in Singapore. Following the recent cases reported across the Causeway, health authorities are on high alert and have heightened mosquito control and health surveillance. State Health and Environment Committee chairman Ling Tian Soon said entry protocols remain unchanged at all land, sea and air checkpoints to Johor. "Singaporeans and other foreigners can continue to make their way into Johor. "Screening protocol will continue at all entry checkpoints…anyone showing symptoms will be immediately referred for further testing at designated medical facilities," he told the New Straits Times today. "There are no reported Zika cases in Johor as of now, and the Health Ministry has not issued any new directives. However, we remain vigilant," Ling added. There are two confirmed Zika cases in Singapore's housing estate in Woodlands, some 5km away from the Johor's border land entry point via the Customs, Immigration and Quarantine (CIQ) complex at the Bangunan Sultan Ismail, here. While Malaysia has not seen a Zika outbreak since 2016, Ling stressed the need for continuous preventive efforts, especially in Johor given its high volume of cross-border traffic. Malaysia's last significant Zika concern occurred in 2016, when the first local transmission was confirmed in Sabah, shortly after Singapore reported a major outbreak in the Aljunied area. Since then, Malaysia has reported sporadic cases, primarily imported or isolated incidents, but no major outbreak or cluster has been officially recorded. As of June 2025, there has been no confirmed Zika outbreak in Malaysia resembling the 2016 episode in terms of scale or transmission pattern. Meanwhile, Singapore National Environment Agency (NEA) in a statement issued on June 19 (Thursday) said NEA and the Communicable Diseases Agency (CDA) confirmed two locally transmitted Zika cases at Woodlands Street 11 and Street 32. The viral traces were found in both mosquito and wastewater samples in the area which signalled a likely transmission. Singapore, has deployed over 70,000 mosquito traps across the island, has recorded seven confirmed Zika cases this year. The virus is spread mainly by Aedes mosquitoes, which is the same vector responsible for dengue. It can cause serious complications in pregnant women, including birth defects. Zika symptoms include fever, rash, red eyes, and joint pain, although many infected individuals remain asymptomatic. There is currently no vaccine or specific treatment. Ling urged Johoreans to stay alert and practise anti-mosquito measures such as removing stagnant water and using repellents. He also advised pregnant women and those planning to travel to affected areas to consult medical professionals if they develop symptoms. The public can follow updates through official channels and are advised to seek immediate medical attention if unwell.
Malaysian Reserve
a day ago
- Malaysian Reserve
Molecular Point-of-Care (mPOC) Market Reaches $1.8 Billion: Kalorama Report Spotlights Rapid PCR Innovation and Expanding Frontiers in STI and HAI Testing
ARLINGTON, Va., June 20, 2025 /PRNewswire/ — Kalorama Information, a leading authority in in vitro diagnostics (IVD) market research, has released Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029, estimating the global mPOC market at $1.8 billion in 2024. The report offers a comprehensive forecast through 2029, highlighting transformative opportunities in respiratory, sexually transmitted, and hospital-acquired infection diagnostics at or near the point of care. 'While the molecular point-of-care market saw unprecedented acceleration during the COVID-19 pandemic, Kalorama's latest analysis reveals it now stands on a firmer foundation with renewed growth expected,' said Justin Saeks, senior market analyst and report author. 'We anticipate an almost double-digit compound annual growth rate for the 'true' mPOC segment as demand spreads beyond COVID to broader respiratory panels, STIs, HAIs, and tropical diseases.' Key Findings from the Report: Respiratory testing dominates the market, with COVID-19, flu, strep, and RSV continuing to drive system adoption, particularly for combination tests. Growth expected in HAIs and STIs, although these will evolve more slowly due to testing infrastructure and workflow differences across care settings. 'True' mPOC segment revenues, which had recently declined, are projected to achieve a substantial CAGR from 2024 to 2029. Kalorama differentiates between 'true' mPOC platforms and near-patient systems, offering detailed segmentation by company, region, and disease target. Abbott and Cepheid lead their respective segments. True mPOC Systems: Compact, fast, CLIA-waived (or with waiver potential), and operable by non-lab personnel. Key players include Abbott (market leader), Roche, Cepheid, QuidelOrtho, BioFire, and Sekisui. Near-Patient Molecular Systems: Encompasses larger non-POC systems and smaller platforms with POC or near-POC potential. BioFire and Cepheid are major competitors, with Cepheid leading this segment. Why It Matters Now The report's release is timely as healthcare providers seek diagnostic solutions that balance speed, accuracy, and accessibility across both developed and resource-limited settings. mPOC systems bring the power of molecular testing to emergency departments, outpatient clinics, nursing homes, mobile labs, and even homes—enabling timely treatment decisions and improving care outcomes. 'POC molecular diagnostics represent one of the most important intersections between innovation and access in global health,' said Alisa Alvich, Marketing Director at Science and Medicine Group, Kalorama Information's parent company. 'Kalorama's analysis shows where this market is headed and what players must consider to stay competitive.' Audience Impact This research is essential for: Product Managers and R&D leaders developing decentralized molecular platforms. Corporate strategy teams evaluating new market opportunities or CLIA-waived innovations. Investors and M&A professionals scouting high-growth segments or acquisition targets. Clinical lab and procurement teams optimizing test menus for decentralized care delivery. With deep dives into market sizing, disease applications, regional dynamics, and competitive intelligence, Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 equips life sciences professionals with the insights needed to navigate a rapidly evolving diagnostics frontier. Get the Report Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 is now available for purchase at: For purchasing inquiries or to schedule a custom consultation, contact:Sheri Davie – Sales Director, Kalorama About Kalorama Information Kalorama Information, part of Science and Medicine Group Inc., is a trusted publisher of market research exclusively focused on the healthcare industry. For over 25 years, Kalorama has delivered accurate, timely, and strategic intelligence to leaders in biotechnology, clinical diagnostics, in vitro diagnostics (IVD), pharmaceuticals, medical devices, and broader healthcare sectors. Originally launched in 1998, Kalorama Information quickly established itself as a premier source of insight into U.S. and global medical markets. Today, Kalorama remains a leading authority on healthcare market dynamics, with a particular emphasis on IVD. Kalorama is best known for its flagship title, The Worldwide Market for In Vitro Diagnostic Tests, an internationally recognized benchmark in the diagnostics field. Other reports published throughout the year cover these and other healthcare topics in greater detail. Our innovative approach to research, combined with deep industry expertise, has made Kalorama a go-to resource for top healthcare companies, strategic planners, investors, and media seeking authoritative market data and trends. With a singular focus on healthcare, Kalorama continues to shape informed decision-making across the industry through comprehensive, evidence-based analysis. Kalorama also works in coordination with other Science and Medicine Group brands, including BioInformatics, which focuses on life science markets and marketing, SDi, the leading source of information on the laboratory life science and analytical instrumentation industry and publisher of IBO, its twice-monthly newsletter, and IMV, which publishes reports and data on the medical imaging and clinical markets. For more information about Kalorama Information and other services offered by Science and Medicine Group, please visit our website.
